اتصل بنا
عن الشركة
ITBMed is a biopharmaceutical company developing specific immunomodulatory biologics for organ transplantation, stem cell transplantation, and gene therapy. The lead candidate drug Siplizumab is a monoclonal antibody in late-stage clinical development, which has shown significant potential in transforming the life for organ transplant patients, by allowing the complete discontinuation of all immunosuppression treatment and restoration of a normal life.
US
مجهول
لم يتم التحقق من الشركة
شفافية الأعمال
- لم يتم التحقق من معلومات الشركة
- اطلب من عملائهم آراءهم
- لم يرد على المراجعات السلبية